GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 50 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Follow-Up Questions
What is the price performance of GHRS stock?
The current price of GHRS is $13.23, it has increased 0.07% in the last trading day.
What are the primary business themes or industries for GH Research PLC?
GH Research PLC belongs to Pharmaceuticals industry and the sector is Health Care
What is GH Research PLC market cap?
GH Research PLC's current market cap is $820.6M
Is GH Research PLC a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for GH Research PLC, including 4 strong buy, 9 buy, 1 hold, 0 sell, and 4 strong sell
